Nada Abu-Shraie – Consultant, Clinical Pharmacist (Drug Information), King Abdulaziz Medical City (KAMC), Saudi Ministry of National Guard – Health Affairs (MNGHA)

Dr. Nada Abu-Shraie gives her insights into the evolving drug evaluation processes in Saudi Arabia, including the progress made on the path towards striking value-based agreements, where the country stands in terms of patient registries and epidemiological data, and Vision 2030's potential impact on the medicine reimbursement landscape.
We hope that our new Saudi HTA agency, with the help of all other stakeholders such as our DPEC, will soon be fully functioning and generating its own outcomes
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:

Related Interviews

Latest Report